Emergent BioSolutions Inc.
EBS
$11.60
$0.756.91%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -29.91% | -22.74% | -18.56% | -0.54% | 2.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.91% | -22.74% | -18.56% | -0.54% | 2.05% |
| Cost of Revenue | -50.89% | -50.11% | -11.86% | -7.93% | 3.20% |
| Gross Profit | 27.07% | 80.44% | -30.76% | 22.48% | -0.95% |
| SG&A Expenses | -41.49% | -32.58% | -25.67% | -19.06% | -12.00% |
| Depreciation & Amortization | 0.15% | 0.15% | 0.62% | -0.76% | -3.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.64% | -42.95% | -15.23% | -10.81% | -1.64% |
| Operating Income | 268.43% | 177.89% | -410.00% | 75.15% | 34.94% |
| Income Before Tax | 162.37% | 132.99% | 88.85% | 80.46% | 76.99% |
| Income Tax Expenses | -23.08% | 475.28% | 919.12% | 62.80% | -2.26% |
| Earnings from Continuing Operations | 136.35% | 123.76% | 76.72% | 74.94% | 73.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 136.35% | 123.76% | 76.72% | 74.94% | 73.16% |
| EBIT | 268.43% | 177.89% | -410.00% | 75.15% | 34.94% |
| EBITDA | 679.66% | 514.21% | -41.89% | 238.23% | 459.76% |
| EPS Basic | 135.32% | 123.23% | 76.89% | 75.68% | 73.83% |
| Normalized Basic EPS | 193.39% | 159.25% | 79.40% | 60.97% | 35.55% |
| EPS Diluted | 131.63% | 121.77% | 75.41% | 74.97% | 73.16% |
| Normalized Diluted EPS | 184.07% | 155.69% | 68.82% | 59.30% | 33.47% |
| Average Basic Shares Outstanding | 2.96% | 3.55% | 3.73% | 3.67% | 3.55% |
| Average Diluted Shares Outstanding | 4.66% | 6.14% | 6.34% | 4.89% | 4.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |